UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

(Mark One)

|X|          QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                  For the quarterly period ended March 31, 1999

            TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                For the transition period from _______ to _______

                           Commission File No. 1-5439

                             DEL LABORATORIES, INC.
                             ----------------------
             (Exact name of registrant as specified in its charter)

            DELAWARE                                          13-1953103
-------------------------------                             ----------------
(State or other jurisdiction of                             (I.R.S. Employer
 incorporation or organization)                             Identification No.)

                    178 EAB Plaza, Uniondale, New York 11556
                    ----------------------------------------
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (516) 844-2020

                            -------------------------

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                        YES  |X|          NO  |_|

The number of shares of Common Stock, $1 par value, outstanding as of May 13,
1999 was 7,306,424.
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES

                                      Index

Part I. FINANCIAL INFORMATION

                                                                            Page
                                                                            ----

Item 1. Financial Statements:

        Consolidated Balance Sheets as of
          March 31, 1999 and December 31, 1998                                 3

        Consolidated Statements of Earnings for the three
          months ended March 31, 1999 and 1998                                 4

        Consolidated Statements of Cash Flows for the
          three months ended March 31, 1999 and 1998                           5

        Notes to Consolidated Financial Statements                             6

Item 2. Management's Discussion and Analysis of Financial
        Condition and Results of Operations                                    9

PART II. OTHER INFORMATION                                                    12

SIGNATURES                                                                    13

All other schedules and compliance information called for by the instructions to
Form 10-Q have been omitted since the required information is not present or not
present in amounts sufficient to require submission.


                                       -2-
<PAGE>

PART 1 - FINANCIAL INFORMATION

Item 1. Financial Statements

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                      MARCH 31, 1999 AND DECEMBER 31, 1998
               (In thousands except for share and per share data)

<TABLE>
<CAPTION>
              Assets                                            March 31   December 31
                                                                  1999         1998
                                                              ----------   -----------
                                                              (UNAUDITED)    
<S>                                                            <C>          <C>      
Current assets:
  Cash and cash equivalents                                    $   1,331    $   3,731
  Accounts receivable, less allowance for
  doubtful accounts of $1,300 in 1999 and 1998, respectively      47,851       47,116
  Inventories                                                     61,021       55,620
  Deferred income taxes, net                                       3,649        3,649
  Prepaid expenses and other current assets                        2,923        2,975
                                                               ---------    ---------
    Total current assets                                         116,775      113,091

Property, plant and equipment, net                                37,356       37,915
Intangibles arising from acquisitions, net                        18,224       18,450
Other assets                                                       7,657        8,018
                                                               ---------    ---------
    Total assets                                               $ 180,012    $ 177,474
                                                               =========    =========

       Liabilities and Shareholders' Equity

Current liabilities:
  Notes payable to bank                                        $      --    $   3,500
  Current portion of long-term debt                                  486          486
  Accounts payable                                                34,480       35,781
  Accrued liabilities                                             16,036       10,024
  Income taxes payable                                               260          572
                                                               ---------    ---------
    Total current liabilities                                     51,262       50,363

Long-term pension liability, less current portion                  7,895        7,895
Deferred income taxes, net                                           719          719
Long-term debt, less current portion                              63,591       59,400
                                                               ---------    ---------
    Total liabilities                                            123,467      118,377
                                                               ---------    ---------

Shareholders' equity:
  Preferred stock $.01 par value, authorized
  1,000,000 shares; no shares issued                                  --           --
  Common stock $1 par value, authorized
  20,000,000 and 10,000,000 shares, respectively;
  issued 10,000,000 shares                                        10,000       10,000
  Additional paid-in capital                                       1,850        1,850
  Accumulated other comprehensive loss                            (1,494)      (1,466)
  Retained earnings                                               81,308       81,204
                                                               ---------    ---------
                                                                  91,664       91,588
Less: Treasury stock, at cost, 2,621,876 shares in 1999
and 2,490,823 shares in 1998                                     (33,864)     (31,097)
Receivables for stock options exercised                           (1,255)      (1,394)
                                                               ---------    ---------
          Total shareholders' equity                              56,545       59,097
                                                               ---------    ---------

    Total liabilities and shareholders' equity                 $ 180,012    $ 177,474
                                                               =========    =========
</TABLE>

         The accompanying notes are an integral part of the consolidated
                              financial statements.


                                       -3-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                       CONSOLIDATED STATEMENTS OF EARNINGS
               FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND 1998
               (In thousands except for share and per share data)
                                  (UNAUDITED)

                                                        THREE MONTHS ENDED

                                                            MARCH 31
                                                            --------
                                                      1999             1998
                                                      ----             ----

Net sales                                          $    61,756      $    65,416

  Cost of goods sold                                    27,774           25,438
  Selling and administrative expenses                   33,895           33,566
                                                   -----------      -----------
      Operating income                                      87            6,412

  Gain on sale of facility                               1,734               --

  Interest expense                                       1,228            1,024
  Interest income                                          (17)            (123)
                                                   -----------      -----------
      Interest expense, net                              1,211              901
                                                   -----------      -----------

Earnings before income taxes                               610            5,511
Income taxes                                               244            2,260
                                                   -----------      -----------
      Net earnings                                 $       366      $     3,251
                                                   ===========      ===========

Earnings per common share:
      Basic                                        $      0.05      $      0.43
                                                   ===========      ===========
      Diluted                                      $      0.05      $      0.39
                                                   ===========      ===========

Weighted average common
  shares outstanding:
      Basic                                          7,471,000        7,628,000
                                                   ===========      ===========
      Diluted                                        7,911,000        8,280,000
                                                   ===========      ===========

         The accompanying notes are an integral part of the consolidated
                             financial statements.


                                       -4-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
               FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND 1998
                                 (In thousands)
                                   (UNAUDITED)

                                                                 March 31
                                                                 --------

                                                             1999        1998
                                                             ----        ----

Cash flows from operating activities:
Net earnings                                               $    366    $  3,251
Adjustments to reconcile net earnings to net cash
  provided by operating activities:
Depreciation and amortization                                 1,758       1,543
Provision for doubtful accounts                                  --          50
Gain on sale of facility                                     (1,734)         --
Other non-cash operating items                                  166         114
Changes in operating assets and liabilities:
    Accounts receivable                                        (735)     (5,816)
    Inventories                                              (5,401)     (5,790)
    Prepaid expenses and other current assets                    52         326
    Other assets                                                361        (664)
    Accounts payable                                         (1,326)     (4,094)
    Accrued liabilities                                       6,012       5,984
    Income taxes payable                                       (312)      1,473
                                                           --------    --------
      Net cash used in operating activities                    (793)     (3,623)
                                                           --------    --------

Cash flows provided by (used in) investing activities:
    Proceeds from sale of facility                            2,538          --
    Property, plant and equipment additions                  (1,750)     (1,678)
    Additions to intangibles and other assets                   (26)         --
                                                           --------    --------

      Net cash provided by (used in) investing activities       762      (1,678)
                                                           --------    --------

Cash flows used in financing activities:
    Borrowings under long-term debt, net of
      principal payments of long-term debt                    4,139          --
    Repayment of short-term borrowings                       (3,500)        (76)
    Acquisition of treasury stock                            (2,480)       (899)
    Dividends paid                                             (524)       (466)
    Other financing activities                                   --          34
                                                           --------    --------

      Net cash used in financing activities                  (2,365)     (1,407)
                                                           --------    --------

Effect of exchange rate changes on cash                          (4)          1
                                                           --------    --------

Net decrease in cash and cash equivalents                    (2,400)     (6,707)

Cash and cash equivalents at beginning of year                3,731      14,979
                                                           --------    --------

Cash and cash equivalents at end of period                 $  1,331    $  8,272
                                                           ========    ========

         The accompanying notes are an integral part of the consolidated
                              financial statements.


                                      -5-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.    Summary of Significant Accounting Policies
      ------------------------------------------

      The accompanying unaudited consolidated financial statements of Del
      Laboratories, Inc. and subsidiaries (the Company) have been prepared in
      accordance with generally accepted accounting principles for interim
      financial information and with the instructions to Form 10-Q. Accordingly,
      they do not include all of the information and footnotes required by
      generally accepted accounting principles for complete financial
      statements. Interim results are not necessarily indicative of results for
      a full year.

      A summary of the Company's significant accounting policies is presented in
      its 1998 Annual Report to Shareholders. Users of financial information
      produced for interim periods are encouraged to refer to the footnotes
      contained in the Annual Report to Shareholders when reviewing interim
      financial results.

      In the opinion of management, the accompanying interim financial
      statements contain all material adjustments, consisting only of normal
      recurring adjustments, necessary to present fairly the consolidated
      financial position, results of operations and cash flows of the Company
      for interim periods.

2.    Inventory
      ---------

      Classification of inventories were as follows (in thousands):

                                          March 31          December 31
                                            1999               1998
                                            ----               ----

            Raw Materials                $  33,453           $ 26,912
            Work In Process                  6,003              6,247
            Finished Goods                  21,565             22,461
                                         ---------           --------
                                         $  61,021           $ 55,620
                                         =========           ========

3.    Earnings Per Share
      ------------------

      Earnings per share is computed in accordance with the provisions of
      Statement of Financial Accounting Standards (SFAS) No. 128, "Earnings per
      Share", which became effective for the Company as of December 31, 1997.
      Basic earnings per share is computed by dividing income available to
      common shareholders (which for the Company equals its recorded net income)
      by the weighted-average number of common shares outstanding during the
      period. Diluted earnings per share reflects the potential dilution that
      could occur if securities or other contracts to issue common stock, such
      as stock options, were exercised, converted into common stock or otherwise
      resulted in the issuance of common stock.


                                       -6-
<PAGE>

3.    Earnings Per Share (continued)
      ------------------------------

      A reconciliation between the numerators and denominators of the basic and
      diluted income per common share is as follows:

                                                         (Amounts in thousands,
                                                         except per share data)

                                                           Three Months Ended 
                                                               March 31
                                                        1999               1998
                                                        ----               ----

Net earnings (numerator)                               $  366             $3,251
                                                       ------             ------
                                                                      
Weighted-average common shares                                        
   (denominator for basic earnings per share)           7,471              7,628
                                                                      
Effect of dilutive securities:                                        
   Employee stock options                                 440                652
                                                                      
Weighted-average common and potential                                 
   common shares outstanding                                          
   (denominator for diluted earnings per share)         7,911              8,280
                                                       ------             ------
                                                                      
Basic earnings per share                               $ 0.05             $ 0.43
                                                       ------             ------
                                                                      
Diluted earnings per share                             $ 0.05             $ 0.39
                                                       ------             ------

      Employee stock options for 237,000 and 1,600 shares for the periods ended
      March 31, 1999 and 1998, respectively, were not included in the net
      earnings per share because their effect would have been anti-dilutive.

4.    Comprehensive Income
      --------------------

      Effective January 1, 1998, the Company adopted SFAS No. 130, "Reporting
      Comprehensive Income". This Statement requires that all items recognized
      under accounting standards as components of comprehensive income be
      reported in a financial statement that is displayed with the same
      prominence as other financial statements. Other comprehensive income may
      include foreign currency translation adjustments, minimum pension
      liability adjustments and unrealized gains and losses on marketable
      securities classified as available for sale. The components of
      comprehensive income for the three months ended March 31, 1999 and 1998
      are as follows:

                                            Three Months Ended
                                                 March 31

                                             1999         1998
                                             ----         ----

      Net income                            $  366       $ 3,251
      Other comprehensive loss:
         Foreign currency translation          (28)          (25)
                                            ------       -------

      Total comprehensive income            $  338       $ 3,226
                                            ======       =======


                                       -7-
<PAGE>

5.    Gain on sale of facility
      ------------------------

      In February, 1999, the Company sold a warehouse facility in Plainview, New
      York for net proceeds of $2.7 million. At December 31, 1998, this facility
      was included in property, plant and equipment and was accounted for as a
      held for sale asset.

6.    Segment Information
      -------------------

      At December 31, 1998, the Company adopted SFAS No. 131, "Disclosures about
      Segments of an Enterprise and Related Information". This statement
      established standards for reporting information about operating segments
      and related disclosure about products and services and geographic areas.
      The Company operates in two segments, Cosmetic and Pharmaceutical, that
      have been organized by the products and services they offer. The Cosmetic
      segment's principal products are nail care, nail color, color cosmetics,
      beauty implements, bleaches and depilatories, personal care products and
      other related cosmetic items. The Pharmaceutical segment's principal
      products are proprietary oral analgesics, acne treatment products and
      first aid products. The accounting policies of the segments are the same
      as those described in the summary of significant accounting policies. The
      Company evaluates the performance of its operating segments based on
      operating income. Certain assets, including property, plant and equipment
      and deferred tax assets, are not allocated to the identifiable segments.
      However, depreciation and amortization of unallocated assets are charged
      to each segment.

                                                    For the period ended
                                                         March 31,
                                                       (in thousands)
                                                        ------------

                                                     1999           1998
                                                     ----           ----

      Net sales
            Cosmetic                               $ 46,701       $ 51,534
            Pharmaceutical                           15,055         13,882
                                                   --------       --------
            Consolidated                           $ 61,756       $ 65,416
                                                   ========       ========

      Operating income (loss)
            Cosmetic                               $ (2,200)      $  4,306
            Pharmaceutical                            2,287          2,106
                                                   --------       --------
            Consolidated                           $     87       $  6,412
                                                   --------       --------

      Gain on asset sale                           $  1,734       $     -- 
                                                   --------       --------
      Interest expense, net                        $  1,211       $    901
                                                   --------       --------
      Earnings before taxes                        $    610       $  5,511
                                                   ========       ========

      Depreciation and amortization
            Cosmetic                               $  1,645       $  1,431
            Pharmaceutical                              113            112
                                                   --------       --------
            Consolidated                           $  1,758       $  1,543
                                                   ========       ========


                                       -8-
<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations

(1)   RESULTS OF OPERATIONS

      Net Sales
      ---------

      Net sales for the first quarter of 1999 were $61.8 million, a decrease of
      5.5% compared to $65.4 million in 1998.

      Cosmetic net sales for the first quarter of 1999 were $46.7 million, a
      decrease of 9.3% compared to $51.5 million in 1998. The decrease is
      principally due to lower shipments of the Naturistics cosmetics and bath &
      body care line. Pharmaceutical net sales for the first quarter of 1999
      were $15.1 million, an increase of 8.6% compared to $13.9 million in 1998.
      The increase is due principally to volume growth in the Orajel family of
      products.

      Cost of Sales
      -------------

      Cost of Sales for the first quarter of 1999 were $27.8 million, or 45.0%
      of net sales, as compared to $25.4 million, or 38.8% of net sales in 1998.
      The increase in cost of sales, as a percentage of net sales, is
      principally attributable to lower shipments and higher product returns of
      the Naturistics cosmetics and bath & body care line and a change in the
      mix of business within the Cosmetic division compared to prior year.

      Selling and Administrative Expenses
      -----------------------------------

      Selling and administrative expenses for the first quarter of 1999 were
      $33.9 million, or 54.9% of net sales, as compared to $33.6 million, or
      51.4% of net sales in 1998.

      Gain on Sale of Facility
      ------------------------

      In February, 1999, the Company sold a warehouse facility in Plainview, New
      York for $2.7 million. At December 31, 1998, this facility was included in
      property, plant and equipment and was accounted for as a held for sale
      asset.

      Net Interest Expense
      --------------------

      Interest expense, net of interest income, for the first quarter of 1999
      was $1.2 million, compared to $.9 million in 1998. The increase is due to
      higher average borrowings during the first quarter of 1999, as compared to
      the first quarter of 1998, principally due to the financing of the
      acquisition of intellectual property rights and other assets of the
      CornSilk brand of facial make-up in May 1998.


                                       -9-
<PAGE>

      Provision for Income Taxes
      --------------------------

      The provision for income taxes is based on the Company's expected
      effective annual tax rate of 40% in 1999 compared to 41% in 1998.

      Net Earnings
      ------------

      Net earnings for the first quarter of 1999 were $.4 million, compared to
      $3.3 million in 1998. The decrease is due primarily to a reduction in
      gross margin as a result of the decrease in net sales of the Naturistics
      cosmetics and bath & body care line and a change in the mix of business
      within the Cosmetic division.

(2)   LIQUIDITY AND CAPITAL RESOURCES

      At March 31, 1999, the Company had cash and cash equivalents of $1.3
      million as compared to $8.3 million at March 31, 1998.

      Net cash used in operating activities was $.8 million for the three months
      ended March 31, 1999, primarily due to an increase in inventories of $5.4
      million to support new product lines and promotional sales, and a decrease
      in accounts payable of $1.3 million, partially offset by an increase in
      accrued liabilities of $6.0 million.

      Cash of $2.5 million was provided by the sale of a facility in the first
      quarter of 1999. Cash used for property, plant and equipment additions was
      $1.8 million for the three months ended March 31, 1999, compared to $1.7
      million in 1998.

      Net cash used in financing activities for the three months ended March 31,
      1999 was $2.4 million, due primarily to the acquisition of treasury stock,
      compared to $1.4 million used in financing activities in 1998.

      The Company believes that cash from future operations, cash on hand and
      amounts available from short-term credit facilities, will be sufficient to
      satisfy the Company's liquidity needs for the foreseeable future.

      Year 2000 Conversion
      --------------------

      The Company is addressing the issue of many existing computer programs
      using only the last two digits to refer to a year. Therefore, these
      computer programs do not properly recognize a year that begins with "20"
      instead of the familiar "19". If not corrected, many computer applications
      could fail or create erroneous results. A committee specifically created
      to resolve Year 2000 issues, led by a member of the Board of Directors and
      comprised of senior corporate executives and an outside expert, as well as
      sub-committees and task forces meet regularly.

      The Company's efforts to identify and address issues relating to its
      readiness for Year 2000 have included the following: the identification
      phase (100% complete) consisting of computer based systems, software,
      third party programs and all hardware including embedded microprocessors.
      The assessment phase (approximately 95% complete) has focused on those
      applications most critical to the business including examination of all
      coding used for date calculations. The remediation phase (approximately
      85% complete) consists of systems changes, where necessary, by
      replacement, modification or upgrade. The testing phase (approximately 45%
      complete) includes full system tests planned during the second quarter of
      1999 at which time systems dates will be rolled forward on test machines
      to check performance and computational accuracy. All significant
      suppliers, customers and financial institutions, as well as all customers
      doing business electronically with the Company, have been contacted in
      order to identify potential areas of concern. It is anticipated that all
      of the above phases will be substantially completed by mid 1999.


                                      -10-
<PAGE>

      Year 2000 Conversion (continued)
      --------------------------------

      The Company currently estimates that remediation costs will not exceed
      $1,000,000 for replacement systems, discovery tools and expenses necessary
      to achieve Year 2000 compliance.

      Improper or inadequate remediation of Year 2000 problems by parties with
      whom the Company does business could adversely affect the Company's supply
      chain and subsequently the ability to effectively manage production and
      distribution activities. In addition, administrative functions essential
      to the day to day operations of the business could be impaired if Year
      2000 remediation is not completed in a timely manner. Due to the general
      uncertainty inherent in the Year 2000 problem, resulting primarily from
      the uncertainty of the Year 2000 readiness of parties with whom the
      Company does business, the Company is unable to determine at this time
      whether the consequences of Year 2000 failures will have a material impact
      on the Company's results of operations, liquidity or financial condition.

      The Company is currently identifying and documenting potential business
      disruptions and continuity planning procedures. The focus of this activity
      is on potential failures of internal and external systems required to
      carry out normal business operations, including services provided by the
      public infrastructure such as electric power, transportation and
      telecommunications. The Company expects this activity to be an on-going
      process well into the third quarter of 1999.

      The above comments on the Year 2000 issue contain forward-looking
      statements relating to the Company's plans, strategies, objectives,
      intentions, and resources that should be read in conjunction with the
      following disclosure on Forward-Looking Statements.

      New Accounting Pronouncements
      -----------------------------

      The Financial Accounting Standards Board issued Statement of Financial
      Accounting Standard No. 133, "Accounting for Derivative Instruments and
      Hedging Activities" (SFAS No. 133), which is effective for fiscal years
      beginning after June 15, 1999. SFAS No. 133 provides guidance for
      accounting for all derivative instruments, including certain derivative
      instruments embedded in other contracts, and for hedging activities. The
      management of the Company does not believe that the implementation of SFAS
      No. 133 will have a significant impact on its financial position or
      results of operations.

      Forward - Looking Statements
      ----------------------------
      Management's Discussion and Analysis of the Results of Operations and
      Financial Condition and other sections of this Form 10-Q include
      "forward-looking statements" within the meaning of Section 27A of the
      Securities Act of 1933 and Section 21E of the Securities and Exchange Act
      of 1934 (the "Exchange Act"). All statements other than statements of
      historical information provided herein are forward-looking statements and
      may contain information about financial results, economic conditions,
      trends and known uncertainties. The forward-looking statements contained
      herein are subject to certain risks and uncertainties that could cause
      actual results to differ materially from those reflected in the
      forward-looking statements. Factors that might cause such a difference
      include, but are not limited to, delays in introducing new products or
      failure of consumers to accept new products, actions by competitors which
      may result in mergers, technology improvement or new product
      introductions, the dependence on certain national chain drug stores and
      mass merchandiser relationships due to the concentration of sales
      generated by such chains, changes in fashion oriented color cosmetics
      trends, and trends in the general economy.

      Readers are cautioned not to place undue reliance on these forward-looking
      statements, which reflect management's analysis, judgment, belief or
      expectation only as of the date hereof. The Company undertakes no
      obligation to publicly revise these forward-looking statements to reflect
      events or circumstances that arise after the date hereof. In addition to
      the disclosure contained herein, readers should carefully review any
      disclosure of risks and uncertainties contained in other documents the
      Company files or has filed from time to time with the Securities and
      Exchange Commission pursuant to the Exchange Act.


                                      -11-
<PAGE>

PART II - OTHER INFORMATION

      Item 6. Exhibits and Reports on Form 8-K
              --------------------------------

            (a)   Exhibit 27.1 Financial Data Schedule

            (b)   Reports on Form 8-K

                  None


                                      -12-
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                                DEL LABORATORIES, INC.
                                                ----------------------
                                                (Registrant)


      Date: May 14, 1999                        /s/ Dan K. Wassong
      ------------------                        ------------------
                                                Dan K. Wassong
                                                Chairman, President and
                                                Chief Executive Officer


      Date: May 14, 1999                        /s/ Enzo J. Vialardi
      ------------------                        --------------------
                                                Enzo J. Vialardi
                                                Executive Vice President and
                                                Chief Financial Officer


                                      -13-
<PAGE>